GlassScriptPhysician profile
Matthew D Lebsack
NPI 1144640517
$2,490.48
in general payments reported to CMS, 2019-2025
22 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.16 · 2020: $56.54 · 2021: $348 · 2022: $80.28 · 2023: $684 · 2024: $739 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,949.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $568.92 | 2021-2025 | |
| Glaxosmithkline, LLC. | $516.16 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $289.69 | 2019-2025 | Airsupra, Breztri |
| Pfizer INC. | $197.43 | 2021-2025 | |
| Astellas Pharma US INC | $188.35 | 2022-2025 | Veozah |
| Lilly USA, LLC | $143.15 | 2023-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $97.51 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $69.55 | 2021-2024 | Eliquis, Camzyos |
| Allergan, INC. | $63.57 | 2019-2021 | |
| Mylan Specialty L.P. | $49.78 | 2023-2024 | Yupelri |
| Novo Nordisk INC | $39.84 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $37.35 | 2024-2025 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $36.86 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $33.32 | 2019 | |
| Inspire Medical Systems, INC. | $26.45 | 2025 | Inspire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $22.07 | 2022 | |
| Insulet Corporation | $21.74 | 2024 | Omnipod |
| Organogenesis INC. | $21.69 | 2024 | |
| Xeris Pharmaceuticals, INC. | $19.67 | 2024 | Gvoke Hypopen |
| Supernus Pharmaceuticals, INC. | $17.98 | 2025 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $16.50 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lebsack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.